期刊文献+

微波消融治疗小鼠黑色素瘤及对肿瘤血管生成的影响 被引量:1

Therapeutic effect of microwave ablation in mice bearing transplanted melanoma through inhibition of angiogenesis
在线阅读 下载PDF
导出
摘要 目的研究微波消融对小鼠黑色素瘤肿瘤负荷、生存期、肿瘤血管生成的影响。方法建立C57BL/6J小鼠B16-BL6黑色素瘤皮下移植模型,随机分成对照组、微波低剂量组、微波中剂量组、微波高剂量组,比较各组瘤重,病理学检测消融后肿瘤坏死、复发情况,免疫组织化学检测VEGF和CD34表达,计算微血管密度(microvesseldensity,MVD),记录其生存期。结果微波消融各组小鼠肿瘤重量较对照组显著减少(P<0.05);病理学观察发现消融病灶肿瘤细胞大量坏死,肿瘤血管破坏;消融后微血管密度MVD计数及血管内皮生长因子(vascularendothelial growth factor,VEGF)表达显著降低(P<0.05);但微波消融各组同对照组比较不具有生存期优势(P>0.05)。结论微波消融可抑制小鼠消融后黑色素瘤病灶血管新生,并减少肿瘤负荷,但并未延长小鼠生存期。 Objective To investigate the therapeutic effect of microwave ablation(MA) in mice bearing transplanted melanoma.Methods C57BL/6J mice were subcutaneously inoculated with B16-BL6 cells.The transplanted colon tumor was treated with low,intermediate and high doses of MA.The tumor volume and recurrence were measured.The survival time of C57BL/6J mice was observed.Microvessel density(MVD) was analyzed by immunohistochemical staining of CD34 in transplanted tumors and the expression of vascular endothelial growth factor(VEGF) was also examined immunohistochemically.Results The tumor sizes in mice treated with MA were significantly smaller than those in model mice(P〈0.05) .Pathological examination revealed that there was tumor vascular destruction and no tumor recurrence in ablation lesions.VEGF expression and MVD were significantly reduced(P〈0.05) .There was no significant difference in survival time between the MA groups and the control group(P〉0.05) .Conclusion Microwave ablation can reduce tumor load by inhibiting angiogenesis of tumor,but may not prolong survival of tumor-bearing mice.
出处 《实用肿瘤杂志》 CAS 北大核心 2011年第6期569-572,共4页 Journal of Practical Oncology
基金 卫生部科技专项基金(W2009BX015)
关键词 黑色素瘤/病理学 黑色素瘤/治疗 微波治疗应用 抗原 CD34/生物合成 内皮生长因子/生物合成 免疫组织化学 melanoma/pathology melanoma/therapy microwaves/therapeutic use antigens CD34/biosynthesis endothelial growth factors/biosynthesis immunohistochemistry
  • 相关文献

参考文献8

  • 1王金清,赵玉斌,梁永强.内皮抑素联合微波消融治疗裸鼠肾癌移植瘤研究[J].实用肿瘤杂志,2010,25(6):631-633. 被引量:2
  • 2章建全,秦志丰,蒋京京,孟进.超声造影监测下射频联合微波消融治疗淋巴结黑素瘤的尝试[J].第二军医大学学报,2006,27(12):1364-1367. 被引量:7
  • 3Alexeev V,Mucci T,Igoucheva O.Immunotherapeutic strategies for the treatment of malignant melanoma. Giornale Italiano di Dermatologia e Venereologia . 2008
  • 4Markovic SN,Erickson LA,Rao RD,et al.Malignantmelanoma in the21st century,part1:epidemiology,risk factors,screening,prevention,and diagnosis. Mayo Clinic Proceedings . 2007
  • 5Boutros C,Somasundar P,Garrean S,et al.Microwave coagulation therapy for hepatic tumors:review of the literature and critical analysis. Surgical Oncology . 2010
  • 6Pinto MP,Badtke MM,Dudevoir ML,et al.Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Research . 2010
  • 7V Bossung,N Harbeck.Angiogenesis inhibitiors in the management of breast cancer. Current Opinion in Obstetrics and Gynecology . 2010
  • 8Markovic SN,Erickson LA,Rao RD,et al.Malignant melanomain the21st century,part2:staging,prognosis,and treatment. Mayo Clinic Proceedings . 2007

二级参考文献12

  • 1Folkman J. Antiangiogenendostatinis in cancer therapy endostatin and its mechanisms of action [ J ]. Exp Cell Rendostatin, 2006,312(5 ) :594 - 607.
  • 2Maepherson GR, Ng SS, Forbendostatin SL, et al. Antiangiogenic activity of human endostatin is HIF-1- independent in vitro and sensitive to timing of treatment in a human saphenous vein assay [ J]. Mol Cancer Ther, 2003,2 (9) : 845 - 854.
  • 3Laln JS, Leppert JT, Yu H, et al. Exprendostatinsion of the vascu larendothelial growth factor family in tumor dissemination and disease free survival in clear call renal cell carcinoma [ J ]. J Clin Oncol, 2005,23 (Suppl) : 387.
  • 4Hanai J, Gloy J, Karumanchi SA, et al. Endostatin is a potential inhibitor of Wnt signaling [ J ]. J Cell Biol, 2002,158(3) :529 - 539.
  • 5Chamberlain JS, Gibbs RA, Ranier JE, et al. Multiplex PCR for the diagnosis of Duchenne muscular dystrophy [ M]. New York: Academic Prendostatins, 1990 : 272 - 281.
  • 6Takahashi I, Emi Y, Hasuda S, et al. Clincal application of hyperther miacombined with anticancer drugs for the treatment of solid tumors [ J]. Surgery, 2002,131 ( 1 Suppl) :78 - 84.
  • 7Little JW.Melanoma:Etiology,treatment,and dental implications[J].Gen Dent,2006,54:61-66.
  • 8Aloia TA,Grubbs E,Onaitis M,et al.Predictors of outcome after hyperthermic isolated limb perfusion:role of tumor response[J].Arch Surg,2005,140:1115-1120.
  • 9Jones EL,Oleson JR,Prosnitz LR,et al.Randomized trial of hyperthermia and radiation for superficial tumors[J].J Clin Oncol,2005,23:3079-3085.
  • 10Ko SH,Ueno T,Yoshimoto Y,et al.Optimizing a novel regional chemotherapeutic agent against melanoma:hyperthermia-induced enhancement of temozolomide cytotoxicity[J].Clin Cancer Res,2006,12:289-297.

共引文献7

同被引文献9

  • 1章建全,秦志丰,蒋京京,孟进.超声造影监测下射频联合微波消融治疗淋巴结黑素瘤的尝试[J].第二军医大学学报,2006,27(12):1364-1367. 被引量:7
  • 2Baade P, Meng X, Youlden D, et al. Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006 [J]. Int J Cancer, 2012,130(1) : 170- 178.
  • 3Alexeev V, Mucei T, Igoucheva O. Immunotherapeutic strategies for the treatment of malignant melanoma [ J]. G Ital Dermatol Venereol, 2008,143(2) : 139-149.
  • 4Markovic S N, Erickson L A, Rao R D, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis [J]. Mayo Clin Proe, 2007,82 (3) : 364-380.
  • 5Markovie S N, Erickson L A, Rao R D, et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment [ J ]. Mayo Clin Proc, 2007,82 (4) : 490-513.
  • 6Martin-Orozco N, Li Y, Wang Y, et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory ceils [J]. Cancer Res, 2010,70(23) : 9581-9590.
  • 7Harlin H, Kuna T V, Peterson A C, et al. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites [J]. Cancer Immunol lmmunother, 2006,55 (10) : 1185-1197.
  • 8Wilczynski J R, Radwan M, Kalinka J. The characterization and role of regulatory T cells in immune reactions [J]. Front Biosci, 2008,13 ( 18 ) : 2266-2274.
  • 9Mulligan J K, Lathers D M, Young M R. Tumors skew endothelial ceils to disrupt NK cell, T-cell and macrophage functions [J], Cancer Immunol Immunother, 2008,57(7) : 951-961.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部